C-reactive protein in cardiovascular risk assessment: a review of the evidence.

Jacob Abraham, Catherine Y. Campbell, Aamir Cheema, T. J. Gluckman, Roger S. Blumenthal, Peter Danyi

Research output: Contribution to journalReview article

Abstract

C-reactive protein (CRP) is an inflammatory biomarker that is strongly associated with coronary heart disease, inflammation, and the metabolic syndrome. Large-scale prospective cohort trials have shown that measurement of CRP may add predictive accuracy to the Framingham risk score, but interpretation of these data are conflicting. In the primary prevention setting, CRP can be used to reclassify patients in low or intermediate Framingham risk score groups to a higher risk category, thus making them eligible for more intensive pharmacologic interventions.

Original languageEnglish (US)
Pages (from-to)119-123
Number of pages5
JournalJournal of the cardiometabolic syndrome
Volume2
Issue number2
DOIs
StatePublished - Jan 1 2007

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'C-reactive protein in cardiovascular risk assessment: a review of the evidence.'. Together they form a unique fingerprint.

  • Cite this